Learn More About our Award
Learn More About ReNeuron
Directorate Change – Catherine Isted appointed as Chief Executive Officer
Preliminary Results for the year ended 31 March 2022
Update on the Technology Transfer and Supply Agreement with Fosun Pharma
Notice of Results – Analyst meeting and Investor presentation
ReNeuron to present at International Society of Cell and Gene Therapy
at 14-08-2022 5:07:00
15 minute delayed share price from London Stock Exchange provided by Euroland.